Orbimed Advisors LLC 89bio, Inc. Transaction History

Orbimed Advisors LLC

3 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 16, 2022	SELL	$3.45 - $14.99 $243,476 - $1.06 Million	-70,573 Reduced 1.89%	3,658,869 $13.8 Million
Q3 2020 Nov 16, 2020	SELL	$24.34 - $38.82 $6.69 Million - $10.7 Million	-275,000 Reduced 6.87%	3,729,442 $95.7 Million
Q4 2019 Feb 14, 2020	BUY	$19.75 - $33.44 $79.1 Million - $134 Million	4,004,442 New	4,004,442 $105 Million

163

108M

73.6K

1.19M

Ticker ETNB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 46,484,500
Market Cap $417M
Description
89bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for the treatment of liver and cardio-metabolic diseases. Its lead product candidate is pegozafermin, a glycoPEGylated analog of fibroblast growth factor 21 for the treatment of nonalcoholic steatohepatitis. The company also int...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.